Synergy of OK-432 and recombinant interleukin 2 in the antitumor immunity induction and the cytotoxic T-lymphocyte generation.
Ujiie
T
T
Department of Experimental Therapeutics, Kanazawa University, Japan.
D000818:Animals; D000911:Antibodies, Monoclonal; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D004357:Drug Synergism; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy* / Q000276:immunology; D007109:Immunity; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000008:administration & dosage; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D010844:Picibanil / Q000008:administration & dosage; D011994:Recombinant Proteins; D013154:Spleen / Q000166:cytology; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology*; D013945:Thymoma / Q000188:drug therapy* / Q000276:immunology
D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D011994:Recombinant Proteins; D010844:Picibanil